TFA Therapeutics (RAJAF) Short term Debt (2020 - 2025)

TFA Therapeutics has reported Short term Debt for 5 years, with the latest figure at $465233.0 in Q4 2025.

• On a quarterly basis, Short term Debt rose 3.81% year-over-year to $465233.0 in Q4 2025; TTM through Dec 2025 was $465233.0, a 3.81% increase from a year earlier, with the FY2025 full-year figure at $465233.0, up 3.81% from the prior year.
• Short term Debt was $465233.0 for Q4 2025 at TFA Therapeutics, up from $448155.0 in the prior quarter.
• The five-year high for Short term Debt was $1.1 million in Q4 2021, with the low at $263628.0 in Q4 2022.
• Average Short term Debt over 4 years is $573229.5, with a median of $456694.0 recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Short term Debt tumbled 76.38% in 2022, then gained 3.81% in 2025.
• Over 4 years, Short term Debt stood at $1.1 million in 2021, then sank by 76.38% to $263628.0 in 2022, then soared by 70.0% to $448155.0 in 2024, then advanced by 3.81% to $465233.0 in 2025.
• The last three Short term Debt figures came in at $465233.0 (Q4 2025), $448155.0 (Q4 2024), and $263628.0 (Q4 2022), per Business Quant data.